Sorin Group divests vascular therapy business unit
Revenues for the nine months ended March 31, 2009 were $29.3 million, a $1.3 million decrease against revenues of $30.6 million for the nine months ended March 31,
Boehringer Ingelheim has signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer.